10th Antibody Industrial Symposium 2022 June 28 - 29 2022 | Montpellier - France
News Twitter


schedule & speakers

Day 1

Tuesday, June 28th 2022


Registration and welcome coffee


Welcome Address



Beyond affinity: antibody discovery, optimisation, and developability screening from mammalian display libraries
IONTAS Peter Slavny

Peter Slavny
CTO and co-founder

Clinical Trials and Translational Investigations into CAR-T Cell Therapy for Cancer
Massachusetts General Hospital Mark Leick

Mark Leick
Instructor at Harvard Medical School and an attending physician in the Hematopoietic Cell Transplant and Cell Therapy Division of Oncology
Massachusetts General Hospital (MGH), USA


Coffee Break - Exhibition Hall - B2B Meetings


Track IO Novel mAb target – BsAbs – Fc-fusion protein/ Rare diseases

Session I

Avelumab internalization by human circulating immune cells is mediated by both Fc gamma receptor and PD-L1 binding
Merck Hulin Jin

Hulin Jin
Associate Director
Merck KGaA, Germany

Merck Berend Neuteboom

Berend Neuteboom
Senior Scientific Director
Merck KGaA, Germany

Engineering T Cells for in vivo Secretion of Tumor-Specific T Cell-Redirecting Bispecific Antibodies
Hospital Universitario 12 de Octubre Luis Alvarez-Vallina

Luis Alvarez-Vallina
Head of the Cancer Immunotherapy Unit
Hospital Universitario "12 de Octubre", Spain

From data to predictions: AI-based virtual screening for multi-specific protein therapeutics
Sanofi R&D Dilyana Dimova

Dilyana Dimova
Data Scientist
Sanofi R&D, Germany

Using AI solutions for antibody discovery and design
Mabsilico Astrid Musnier

Astrid Musnier
Cofounder and head of biology
MAbSilico, France

Track Adoptive cell therapy & Gene Editing

Session I

Accessible and affordable CAR-T cell production in academia
IDIBAPS-Hospital Clínic Manel Juan Otero

Manel Juan Otero
Head of Immunology Service at Hospital Clínic de Barcelona
IDIBAPS-Hospital Clínic, Spain

What does it take in research to develop gene and cell therapies
Kuopio Center for Gene and Cell Therapy Tuija Kekarainen

Tuija Kekarainen
Cell Therapy Unit Director
Kuopio Center for Gene and Cell Therapy (KCT), Finland

Writing the Future of Cell Therapies using the Twist Biopharma Library of Libraries
Twist Bioscience Leonie Alten

Leonie Alten
Scientific Development Manager, Synthetic Biology
Twist Bioscience, Germany

Cell Avidity: a Crucial Parameter in Understanding T-Cell Interactions in Immunotherapy and predicting in-vivo performance
Lumicks Peter Djali

Peter Djali
BD Manager, Cell Avidity
Lumicks, UK

Cell based assays for evaluating immunogenicity in gene and cell therapies
Synexa Matti Kimberg

Matti Kimberg
Chief Scientific Officer
Synexa, UK


Lunch break - Exhibition Hall - B2B Meetings


Track IO Novel mAb target – BsAbs – Fc-fusion protein/ Rare diseases

Session II

Antibody engineering for the generation of potent NK cell engagers via triggering NKp30
Merck Stefan Zielonka

Stefan Zielonka
Director, Protein Engineering & Antibody Technologies
Merck Healthcare KGaA, Germany

PVRIG and TIGIT immune checkpoint blockade in cancer: Emerging translational data from clinical trials
Compugen Pierre Ferré

Pierre Ferré
VP Preclinical Development
Compugen, Israel

The power of specificity screening in end-to-end antibody candidate selection
Charles River Diogo Rodrigues Ferreirinha

Diogo Rodrigues Ferreirinha
European Senior Account Manager
Charles River, UK

Charles River Ed McGowan

Ed McGowan
Director of Advanced Modalities
Charles River, UK

Recombinant Antibody Production:Novel Antibody Generation Platforms
Sino Biological Inc Chen Yuning

Chen Yuning
R&D Manager
Sino Biological Inc, USA

Track Adoptive cell therapy & Gene Editing

Session II

Preclinical models to assess safety and efficacy of engineered T cells
Institut Cochin Emmanuel Donnadieu

Emmanuel Donnadieu
Group Leader
Institut Cochin, France

Harnessing the Unique Features of Macrophage Therapies with CAR Technology (CAR-M) to Fight Solid Tumors
Carisma Therapeutics Sascha Abramson

Sascha Abramson
Vice President, Scientific Operations
Carisma Therapeutics, USA

High quality DNA fragments enable high-throughput applications
Integrated DNA Technologies. Inc. Katja Schreiter

Katja Schreiter
Director Strategic Accounts EMEA
Integrated DNA Technologies. Inc., Germany

Intelligent cold chain solution
Cell&Co Nicolas Demoures

Nicolas Demoures
Sales Manager
Cell&Co, France

CRISPR as non-viral approach for Therapies
GenScript Linda Tchatchouang

Linda Tchatchouang
Executive - France & Benelux
GenScript, France

OpenSPR & Alto: Nicoya's Label-Free Solutions for Biologics Research Take the complexity out of SPR and empower your team with the data you need
Proteigene Nicoya Nicolas Carvou

Nicolas Carvou
EMEA Business Development Manager
Nicoya, UK


Coffee Break - Exhibition Hall - B2B Meetings


Pitch Session : Innovative Approaches and New trend Technologies

Call for Abstracts until April 1st 2022

Non-genetically modified, CAR-like, NK cells
Inserm U1183 Loïs Coënon

Loïs Coënon
PhD Student
Inserm U1183, Université de Montpellier, Institute for Regenerative Medicine & Biotherapy (IRMB)

Targeting βig-h3-a key stromal protein in cancer
StromaCare Ana Hennino

Ana Hennino
StromaCare, France

Design of specific Ral GTPase isoform intrabodies to target cancer progression
IRCM Charlotte Sarre

Charlotte Sarre
Institut de Recherche en Cancérologie de Montpellier (IRCM) INSERM U1194, France

Nanobody active inside the cell against TAU aggregation
Hybrigenics Jean-Christophe Gillet

Jean-Christophe Rain
Hybrigenics Services, France

Adcitmer®, a new CD56-targeting monomethyl auristatin E-conjugated antibody, is a potential therapeutic approach in Merkel cell carcinoma
University of Tours Clara Esnault

Clara Esnault
PhD Student
UMR 1282 ISP INRAE University of Tours, France

Computer Based Antibody bank screening
mAbSilico Adrien Verdier

Adrien Verdier
Data Scientist
mAbSilico, France

Antibody diffusion in solid tumors: key role of affinity/avidity in « on target/off tumor »
IRCM Matthieu Gracia

Matthieu Gracia
Institut de Recherche en Cancérologie de Montpellier (IRCM) INSERM U1194, France

Immunomodulatory therapy with anti-cathepsin D antibody in a mouse triple-negative breast cancer model
IRCM Timothée David

Timothée David
Institut de Recherche en Cancérologie de Montpellier (IRCM) INSERM U1194, France

Intellectual Property : Where do we go from now ?

Sponsored by REGIMBEAU

Antibodies and Artificial Intelligence
REGIMBEAU Raphaëlle Gillet

Raphaëlle Gillet
European & French Patent Attorney

REGIMBEAU Nicolas Bouquin

Nicolas Bouquin
Senior Associate, European & French Patent Attorney

Patent protection beyond the antibody sequence
Mathys & Squire Juliet Redhouse

Juliet Redhouse
Partner, UK & European Patent Attorney
Mathys & Squire, UK

European Patent Law Reloaded – The Unitary Patent System
Michalski Hüttermann & Partner Chris Volpers

Chris Volpers
Partner, German & European Patent Attorney
Michalski Hüttermann & Partner, Germany




Cocktail Gala Dinner

Day 2

Wednesday, June 29th 2022


Welcome coffee


Track Antibodies-based Immunotherapies : latest advancements

Session I

Engineering antibodies for immune stimulation
University Southampton Mark Cragg

Mark Cragg
Professor of Experimental Cancer Biology
University Southampton, UK

Anticancer IgA-based immunotherapies
Amsterdam UMC Marjolein Van Egmond

Marjolein Van Egmond
Professor Oncology and Inflammation
Amsterdam UMC, The Netherlands

Academy and industry: discovery and development of therapeutic phage display-derived anti-Spike antibodies
Technische Universität Braunschweig Federico Bertoglio

Federico Bertoglio
Post-doctoral researcher
Technische Universität Braunschweig, Germany

Track New Tools & Methods to accelerate Analytical & Characterization of Biotherapeutics

Multi-level structural characterization of mAbs, ADCs, BsAbs, Fc-fusion proteins and ImmunoCytokines
Pierre Fabre Alain Beck

Alain Beck
Senior Director, Biologics CMC & Developability
Pierre Fabre, France

Glycoform-resolved pharmacokinetic studies in a rat model employing glycoengineered variants of a therapeutic monoclonal antibody
Roche Diagnostics GmbH Dietmar Reusch

Dietmar Reusch
Director Development Analytics Characterization
Roche Diagnostics GmbH, Germany

In depth characterization of Nanobody® and SynthorinTM molecules as new biotherapeutic modalities by LC-MS
Sanofi Udo Roth

Udo Roth
Laboratory Head Mass Spectrometry CMC Development / Bioanalytics
Sanofi, Germany

2D-LC/MS workflows for the automated analysis of in-process samples and for the characterisation of mAbs in a GMP regulated environment
Quality Assistance Géry Van Vyncht

Géry Van Vyncht
Scientific Director
S&I Dpt, Quality Assistance, Belgium


Coffee Break - Exhibition Hall - B2B Meetings


Track Antibodies-based Immunotherapies : latest advancements

Session II

CALY-002, antibody inhibiting Interleukin-15 (IL-15) for treatment of several gastrointestinal indications
Calypso Biotech Alain Vicari

Alain Vicari
CEO & Co-Founder
Calypso Biotech, Switzerland

In vivo validation in a humanized model of the therapeutic potential of hybrid Fc/citrullinated peptide biomolecules : the Cure RA project
IRMB Christian Jorgensen

Christian Jorgensen
Director IRMB, Group Leader of the 'Mesenchymal stem Cells', coordinator of the ECellFrance & Cartigen platforms
CHRU Montpellier, France

Inserm Guy Serre

Guy Serre
Project Leader
Inserm (U1291) INFINITY - Institut toulousain des maladies infectieuses et inflammatoires
Université Toulouse III, France

T cell help and NK cell mediated antibody dependent cellular cytotoxicity
Iowa University George Weiner

George Weiner
Holden Comprehensive Cancer Center, Iowa University, USA

Track Complex Biologics CMC & Developability

An update on immunogenicity of therapeutic antibodies
CEA Saclay Bernard Maillere

Bernard Maillere
Head, laboratory of cellular immunology and biotechnology
CEA Saclay, France

Setting the Stage for Tolerance in Biologics Therapy
EpiVax Amy Rosenberg

Amy Rosenberg
Senior Director of Immunology and Protein Therapeutics
EpiVax, USA

ARGX-117, an inhibitory C2 antibody with sweeping properties leading to sustained in vivo activity
ArgenX Tim Delahaye

Tim Delahaye
ArgenX, Belgium


Lunch break - Exhibition Hall - B2B Meetings


Track Driving innovative drugs into clinical success

Support by Fondation ARC Fondation ARC

Monalizumab, a first in class NK/T cells checkpoint inhibitor
Innate Pharma Stéphanie Cornen

Stéphanie Cornen
Director Program Management
Innate Pharma, France

The butyrophilin (BTN) gene family: from milk fat to the regulation of the immune response including Vγ9Vδ2 T cells and patients treatment
ImCheck Daniel Olive

Daniel Olive
Chairman of Tumor Immunology CRCM and Institut Paoli Calmettes
Scientific Founder of ImCheck, France

Enhancing Efficacy and Safety of 4-1BB Agonism with PRS-343, a Tumor-Targeted Bispecific
Pieris Pharmaceuticals Thomas Jaquin

Thomas Jaquin
Associate Director
Pieris Pharmaceuticals, Germany

Track Manufacturing and bringing into the market

Sponsored by 3Biotech

An agile CMC strategy and plan based on 3 Pillars to accelerate the manufacturing of the therapeutic antibodies
3Biotech Olivier Favre-Bulle

Olivier Favre-Bulle
3Biotech, France

The protein triathlon, Mastering the disciplines of mAb, Bi-Specific and Non-mAb Development & Production
Lonza Antony Munn

Antony Munn
Head of Development Services
Lonza, UK

How AI, ML and intensified continuous manufacturing technologies can support biologics pipeline from lead generation to BLA
Just Evotec Biologics Christelle Dagoneau

Christelle Dagoneau
Senior VP, Global Business Development
Just Evotec Biologics France

International Nonproprietary Names (INN) for monoclonal antibodies: an evolving nomenclature system
World Health Organization Raffaella Balocco Mattavelli

Raffaella Balocco Mattavelli
Unit Head, International Nonproprietary Names Programme (INN) and Classification of Medical Products
World Health Organization, Switzerland


Closing Keynotes

Comprehensive bioassay for therapeutic antibodies against SARS-CoV-2
Food And Drug Administration Baolin Zhang

Baolin Zhang
Senior Investigator, Biologics CMC Leader, SBRBPAS Expert
Food And Drug Administration (FDA) USA

mRNA-1944, a lipid nanoparticle-encapsulated messenger RNA encoding the heavy and light chains of a CHIKV-specific monoclonal neutralizing antibody
Moderna Allison August

Allison August
Vice President, Clinical Development, Infectious Diseases
Moderna, USA


Best Poster - Announcement of AIS2023


End of Congress

Organization contact
Ana Antunes
17 rue Crépet
69007 Lyon
+33 (0)4 78 02 39 91